Tag Archive for: Technology

Bionical Solutions Appoints Chief Technology Officer to Create Innovative Data Products and Software for the Digital Business

WILLINGTON, England, Feb. 29, 2024 – Bionical Solutions, a leading provider of technology enabled engagement and healthcare services to global pharmaceutical, biotech, healthcare companies and the NHS, today announced the appointment of Andrew Seward as Chief Technology Officer for the Digital business. Read more…

Enhanc3D Genomics raises £10 million in Series A financing to advance GenLink3D proprietary technology platform

Cambridge, UK, 20th October 2022: Enhanc3D Genomics (“Enhanc3D”), a functional genomics company unlocking the full potential of the human 3D genome to transform therapeutic development, today announces it has raised £10 million in Series A financing to accelerate the development of its proprietary technology platform – “GenLink3DTM”. The financing was led by BGF and Parkwalk Advisors, […]

Synaffix Wins ‘Best ADC Platform Technology’ Award Again at World ADC Awards Ceremony 2022

AMSTERDAM, NETHERLANDS – 15th September 2022 — Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that the Company was awarded ‘Best ADC Platform Technology’ at the World ADC Conference 2022. Read more…

ENHANC3D GENOMICS Awarded QuickFire Challenge Grant

Cambridge, UK – 26 May 2022: ENHANC3D GENOMICS (“Enhanc3D”), a biotechnology company unlocking the full potential of the human 3D genome to accelerate patient-centric medicine, announces it has been selected as one of the awardees under Johnson & Johnson Innovation’s Immunology Innovations QuickFire Challenge.

Genmab and Synaffix Enter into License Agreement for ADC Technology

Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies Genmab secures rights for conducting research on ADCs against multiple drug targets with options for exclusive worldwide development and commercialization of resulting therapies Synaffix to receive an upfront payment of USD $4.5 million with a total deal value of up to USD $415 million plus […]